T1	Participants 708 781	6000 subjects from a geographically defined population in northern Sweden
T2	Participants 911 919	patients
T3	Participants 1027 1030	917
T4	Participants 1068 1082	Three-quarters
T5	Participants 1175 1212	1773 (30% of 5997) untreated subjects
T6	Participants 1554 1588	for drug-treated subjects under 60
T7	Participants 1707 1728	the medium-risk group
T8	Participants 1775 1781	groups
T9	Participants 2209 2237	low- and medium-risk groups.
